| abstract |
This document provides procedures for the treatment and prevention of pancreatitis, such as glucagon-like peptide agonists (GLP)-induced pancreatitis (such as GLP-1 agonists, for example Byetta (r)), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors and vitamin D receptor agonist precursors). In some examples, the subject has diabetes, such as type 2 diabetes. |